Tag : CARDIOVASCULAR (CV) EVENTS

RESEARCH SPOTLIGHT

Exploring the association of systemic glucocorticoids and incident major adverse cardiovascular events in patients with rheumatoid arthritis based on real-world data
Despite their exceptional anti-inflammatory properties, the use of systemic glucocorticoids (GCs) for the treatment of rheumatoid arthritis (RA) remains controversial due to the potential side effects, particularly their role in elevating patients’ risk of cardiovascular (CV) events. A po

Dr. So, Ho

Assistant Professor, Division of Rheumatology, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong

Ann Rheum Dis. 2023

So H, et al. Time and dose-dependent effect of systemic glucocorticoids on major adverse cardiovascular event in patients with rheumatoid arthritis: a population-based study.